Edward Tenthoff

Q: How accurate are Edward Tenthoff's stock ratings?

About 44% of Edward's ratings were profitable over a one-year hold, with an average return of +0.9% per rating, measured by 13Foresight from historical prices.

Q: How is Edward ranked?

Edward Tenthoff is ranked #1809 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Piper Sandler

Wall Street Analyst

★★★☆☆

#1809

on 13Foresight · ranked by our own returns

44%

Success Rate

-1.2%

Average Return

47 of 106 calls profitable · -9.0% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 44% of Edward Tenthoff's ratings turned a profit when each position was held for 2 year — averaging -1.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

155 Buy 3 Hold 1 Sell

Edward's Stock Coverage 70 ratings · 2026-11-09

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return	vs S&P 500 ⓘ
ALNY Alnylam Pharma	Oct 30, 2026	BUY	Strong Buy +76.3% avg upside 53 analysts	$410.00 148.39% Upside	-5.5%	·
BMEA Biomea Fusion	Oct 29, 2026	BUY	Strong Buy +1905.7% avg upside 16 analysts	$4.00 525.39% Upside	-9.0%	·
MRNA Moderna	Oct 26, 2026	BUY	Hold -48.5% avg upside 38 analysts	$230.00 3.81% Upside	+27.8%	·
FATE Fate Therapeutics	Oct 26, 2026	BUY	Buy +482.8% avg upside 31 analysts	$8.00 284.56% Upside	-10.7%	·
INO Inovio Pharmaceuticals	Oct 21, 2026	BUY	Buy +1300.8% avg upside 19 analysts	$4.00 564.01% Upside	+102.5%	·
OPK Opko Health	Oct 16, 2026	BUY	Buy +284.6% avg upside 12 analysts	$4.00 140.89% Upside	+8.5%	·
ARWR Arrowhead Pharmaceuticals	Oct 15, 2026	BUY	Strong Buy +26.6% avg upside 29 analysts	$126.00 110.30% Upside	-0.6%	·
GENB Generate Biomedicines, Inc.	Oct 14, 2026	BUY	Strong Buy +85.3% avg upside 6 analysts	$26.00 79.75% Upside	+13.1%	·
IBRX ImmunityBio	Oct 14, 2026	BUY	Strong Buy +46.5% avg upside 12 analysts	$16.00 92.98% Upside	-13.9%	·
IPSC Century Therapeutics	Oct 06, 2026	BUY	Strong Buy +262.3% avg upside 11 analysts	$4.00 172.14% Upside	+26.1%	·
GLUE Monte Rosa Therapeutics	Oct 02, 2026	BUY	Strong Buy +108.5% avg upside 16 analysts	$37.00 243.95% Upside	+0.7%	·
DYN Dyne Therapeutics	Sep 29, 2026	BUY	Buy +116.3% avg upside 31 analysts	$47.00 181.61% Upside	+11.5%	·
CAMP CAMP4 Therapeutics Corporation	Sep 29, 2026	BUY	Strong Buy +144.9% avg upside 11 analysts	$15.00 278.74% Upside	+0.1%	·
CTMX CytomX Therapeutics	Sep 23, 2026	BUY	Strong Buy +361.2% avg upside 21 analysts	$12.00 412.91% Upside	-21.2%	·
ARVN Arvinas Holding Company	Sep 14, 2026	BUY	Buy +258.0% avg upside 28 analysts	$20.00 154.48% Upside	-11.7%	·
CAPR Capricor Therapeutics	Sep 01, 2026	BUY	Strong Buy +332.6% avg upside 12 analysts	$25.00 291.85% Upside	-10.1%	·
MESO Mesoblast	Aug 27, 2026	BUY	Strong Buy +66.8% avg upside 14 analysts	$39.00 157.18% Upside	-22.4%	·
ACRV Acrivon Therapeutics, Inc.	Aug 13, 2026	BUY	Strong Buy +762.0% avg upside 13 analysts	$8.00 382.01% Upside	-13.0%	·
CRDF Cardiff Oncology	Aug 12, 2026	BUY	Buy +1092.6% avg upside 18 analysts	$6.00 574.55% Upside	-12.1%	·
XNCR Xencor	Aug 06, 2026	BUY	Strong Buy +31.8% avg upside 29 analysts	$33.00 10.76% Upside	+68.7%	·
CRSP Crispr Therapeutics AG	Aug 04, 2026	BUY	Buy +45.6% avg upside 41 analysts	$110.00 113.86% Upside	-6.1%	·
KPTI Karyopharm Therapeutics	Jul 31, 2026	BUY	Strong Buy +2682.1% avg upside 18 analysts	$7.00 957.35% Upside	·	·
LEGN Legend Biotech	Jun 15, 2026	BUY	Strong Buy +182.3% avg upside 27 analysts	$64.00 195.89% Upside	-34.1%	·
NXTC NextCure	Jun 10, 2026	BUY	Strong Buy +182.1% avg upside 10 analysts	$15.00 137.66% Upside	+139.0%	·
FULC Fulcrum Therapeutics	Jun 02, 2026	SELL	Buy +169.6% avg upside 14 analysts	$3.00 19.10% Downside	-17.2%	·
MIST Milestone Pharmaceuticals	May 14, 2026	BUY	Strong Buy +910.3% avg upside 8 analysts	$7.00 858.84% Upside	-54.6%	·
SKYE Skye Bioscience	May 12, 2026	BUY	Strong Buy +3616.1% avg upside 9 analysts	$48.00 3649.94% Upside	-84.8%	·
MCRB Seres Therapeutics	Feb 13, 2026	HOLD	Buy +836.2% avg upside 11 analysts	$20.00 1029.91% Upside	-78.2%	·
KYMR Kymera Therapeutics	Dec 09, 2025	BUY	Strong Buy -9.6% avg upside 39 analysts	$125.00 1.22% Downside	+51.6%	·
STRO Sutro Biopharma	Dec 04, 2025	BUY	Strong Buy +357.6% avg upside 22 analysts	$20.00 119.83% Upside	+2.6%	·
CUE Cue Biopharma	Apr 01, 2025	BUY	Strong Buy -10.7% avg upside 10 analysts	$2.00 90.42% Downside	-11.1%	·
TPST Tempest Therapeutics	Mar 28, 2025	BUY	Buy +4215.3% avg upside 18 analysts	$65.00 13018.08% Upside	-95.4%	·
XFOR X4 Pharmaceuticals	Feb 07, 2025	BUY	Strong Buy +613.0% avg upside 16 analysts	$60.00 1690.98% Upside	-80.7%	·
SYRS Syros Pharmaceuticals	Oct 23, 2024	BUY	Buy +2937400.0% avg upside 9 analysts	$5.00 1249899.93% Upside	·	·
BCYC Bicycle Therapeutics	Nov 03, 2023	BUY	Strong Buy +557.2% avg upside 21 analysts	$52.00 1320.83% Upside	-53.2%	·
OBX Obsidian Therapeutics	Aug 17, 2023	HOLD	Strong Buy +14.6% avg upside 11 analysts	$0.50 96.60% Downside	·	·
ATYR aTyr Pharma	Apr 11, 2023	BUY	Buy +69.8% avg upside 17 analysts	$13.00 163.13% Upside	·	·
INFIQ Infinity Pharmaceuticals	Feb 23, 2023	HOLD	Buy +647142757.2% avg upside 8 analysts	$0.30 29999900.09% Upside	·	·
SYRE Spyre Therapeutics	Oct 27, 2022	BUY	Strong Buy +1.0% avg upside 25 analysts	$37.50 61.13% Downside	+144.3%	·
PRTCY PureTech Health	Aug 25, 2022	BUY	Strong Buy +224.3% avg upside 3 analysts	$44.00 179.85% Upside	-26.4%	·
APVO Aptevo Therapeutics	Aug 12, 2022	BUY	Strong Buy +817.7% avg upside 4 analysts	$13.00 870.11% Upside	·	·
ELOX Eloxx Pharmaceuticals	May 23, 2022	BUY	Strong Buy +168.9% avg upside 13 analysts	$60.00 346.15% Upside	·	·
KLDO Kaleido Biosciences	Jan 30, 2022	BUY	Buy +13249900.0% avg upside 5 analysts	$4.00 3999899.91% Upside	·	·
VRTX Vertex Pharmaceuticals	Oct 18, 2021	BUY	Strong Buy -20.5% avg upside 62 analysts	$323.00 42.29% Downside	+103.3%	·
SYBX Synlogic	Sep 20, 2021	BUY	Buy +2407.4% avg upside 11 analysts	$9.00 837.43% Upside	·	·
CYTK Cytokinetics	Aug 08, 2021	BUY	Strong Buy +43.4% avg upside 36 analysts	$40.00 36.53% Downside	+0.2%	·
EXEL Exelixis	Jun 28, 2021	BUY	Buy -34.0% avg upside 34 analysts	$36.00 48.21% Downside	+5.4%	·
ARGX Argenx Se	Jun 07, 2021	HOLD	Strong Buy -8.2% avg upside 48 analysts	$250.00 71.93% Downside	+50.7%	·
GB:0QW0 arGEN X	Feb 04, 2021	HOLD	Strong Buy -23.5% avg upside 25 analysts	$275.75 65.77% Downside	+14.7%	·
MTNB Matinas BioPharma	Jun 30, 2020	BUY	Buy +817.2% avg upside 7 analysts	$1.50 0.59% Downside	·	·
MRKR Marker Therapeutics	May 12, 2020	HOLD	Strong Buy +1378.9% avg upside 9 analysts	$2.50 155.09% Upside	-86.9%	·
GILD Gilead Sciences	Mar 20, 2020	BUY	Strong Buy -27.3% avg upside 66 analysts	$90.00 47.33% Downside	-11.7%	·
CFRXQ ContraFect	Dec 11, 2019	BUY	Buy +10969999900.0% avg upside 10 analysts	$10.00 999999899.96% Upside	·	·
LRMR Larimar Therapeutics	Sep 05, 2019	HOLD	Strong Buy +621.1% avg upside 22 analysts	$60.00 2329.17% Upside	+76.1%	·
SRPT Sarepta Therapeutics	Jun 21, 2019	BUY	Buy +223.8% avg upside 50 analysts	$208.00 1017.02% Upside	-39.3%	·
BAYRY Bayer	Jun 04, 2019	BUY	Buy +195.2% avg upside 9 analysts	$32.00 128.81% Upside	+12.8%	·
NVAX Novavax	Feb 28, 2019	SELL	Buy +130.2% avg upside 20 analysts	$5.00 50.42% Downside	·	·
ONCSQ OncoSec Medical	Dec 12, 2018	BUY	Strong Buy +4699999899.9% avg upside 9 analysts	$30.00 2999999899.92% Upside	·	·
VCEL Vericel	Nov 06, 2018	BUY	Strong Buy +16.2% avg upside 16 analysts	$19.00 52.76% Downside	+35.0%	·
VJET Flyte Aviation	Oct 22, 2018	BUY	Buy +3989.3% avg upside 5 analysts	$23.00 3818.92% Upside	·	·
ANTH Anthera Pharmaceuticals	Mar 12, 2018	SELL	Buy +4728471.5% avg upside 9 analysts	$0.10 99900.10% Upside	·	·
REGN Regeneron	Sep 11, 2017	BUY	Strong Buy -12.2% avg upside 60 analysts	$557.00 39.95% Downside	-36.4%	·
VIVS VivoSim Labs	Feb 09, 2017	BUY	Buy +1759.6% avg upside 5 analysts	$4.00 2487.39% Upside	·	·
SVRA Savara	Sep 07, 2016	BUY	Strong Buy +80.0% avg upside 17 analysts	$1.00 79.16% Downside	·	·
DAL Delta Air Lines	Aug 18, 2016	BUY	Strong Buy +9.4% avg upside 32 analysts	$35.00 56.35% Downside	+56.8%	·
ATHXQ Athersys	Jul 09, 2015	HOLD	Buy +2996428471.4% avg upside 8 analysts	$1.00 99999900.10% Upside	·	·
IONS Ionis Pharmaceuticals	Jul 23, 2013	SELL	Strong Buy +74.1% avg upside 44 analysts	$20.00 54.06% Downside	-89.1%	·
ONCY Oncolytics Biotech	Mar 04, 2013	BUY	Strong Buy +1479.8% avg upside 12 analysts	$6.00 1310.51% Upside	·	·
CRIS Curis	Feb 20, 2013	BUY	Strong Buy +2085.2% avg upside 12 analysts	$6.00 900.09% Upside	·	·
SLS SELLAS Life Sciences Group	Dec 31, 2012	BUY	Buy +606.9% avg upside 16 analysts	$2.50 74.22% Downside	·	·

🔒 65 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Edward Tenthoff — Frequently Asked Questions

How accurate are Edward Tenthoff's stock ratings?

Based on the calls 13Foresight could measure, about 44% of Edward's ratings were profitable over a one-year hold, with an average return of +0.9% per rating, or +26.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Edward ranked on 13Foresight?

Edward Tenthoff is currently ranked #1809 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Edward cover?

Edward most recently has ratings on ALNY, BMEA, MRNA, FATE, INO, OPK, ARWR, GENB, IBRX, IPSC, GLUE, DYN and 58 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Edward Tenthoff

Rating Distribution

Welcome to 13Foresight!